BioSpace News Archive

These certifications highlight the company’s relentless focus on security and compliance when it comes to the world’s most personal information: genomic data.

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced data featured yesterday during the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) held in Orlando, FL, December 8-11, 2019

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the results of a pre-planned, blinded interim analysis of safety and tolerability, the primary endpoint of its ongoing Phase 1b/2a clinical trial of its lead therapeutic candidate, ATYR1923, in patients with pulmonary sarcoidosis.

CNSI, a leading business solutions provider in developing and delivering innovative health information technology solutions, announced today that veteran operations executive Bob McCord has joined the company as President and Chief Operating Officer (COO)

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a progress update on FUROSCIX® including progress on both the drug and device validation, and the successful completion of the human factors program.

Silverback Therapeutics, Inc., a biopharmaceutical company developing a pipeline of systemically delivered, locally active therapies, announced the presentation of preclinical data supporting development of its lead ImmunoTAC™ candidate, SBT6050, at the San Antonio Breast Cancer Symposium.

Sunovion Pharmaceuticals Inc. (Sunovion) today announced results from study SEP361-202 which evaluated the long-term safety and effectiveness of SEP-363856, a novel non-dopamine 2 (D2) agent under investigation for the treatment of patients with schizophrenia.

VirTrial, a portfolio company of Kinderhook Industries, LLC, announced today the acquisition of SnapMD, an industry-leading provider of telemedicine tools and services that improve patient engagement.

Daniel O’Connor, President, Director & CEO of OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today sent the following letter to shareholders.

Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, has launched PURECANE™ Brand Sweetener on its new website, www.purecane.com for consumers